PE19312009A1 - Frame domain proteins based multivalent fibronectin - Google Patents

Frame domain proteins based multivalent fibronectin

Info

Publication number
PE19312009A1
PE19312009A1 PE2009000713A PE0007132009A PE19312009A1 PE 19312009 A1 PE19312009 A1 PE 19312009A1 PE 2009000713 A PE2009000713 A PE 2009000713A PE 0007132009 A PE0007132009 A PE 0007132009A PE 19312009 A1 PE19312009 A1 PE 19312009A1
Authority
PE
Peru
Prior art keywords
amino acid
acid sequence
fg
de
bc
Prior art date
Application number
PE2009000713A
Other languages
Spanish (es)
Inventor
Ray Camphausen
Eric Furfine
Irvith M Carvajal
Marco M Gottardis
Joan Carboni
Ricardo M Attar
H Nicholas Marsh
Original Assignee
Squibb Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US12865108P priority Critical
Priority to US21298209P priority
Priority to US17839509P priority
Application filed by Squibb Bristol Myers Co filed Critical Squibb Bristol Myers Co
Publication of PE19312009A1 publication Critical patent/PE19312009A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2318/00Antibody mimetics or scaffolds
    • C07K2318/20Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Abstract

SE REFIERE A UN POLIPEPTIDO DESINMUNIZADO QUE COMPRENDE: A) UN DOMINIO N-TERMINAL QUE CONSTA DE UN PRIMER DECIMO DOMINIO DE FIBRONECTINA DE TIPO III (10Fn3) QUE POSEE i)BUCLES AB, BC, CD, DE, EF Y FG, ii) TIENE AL MENOS UN BUCLE SELECCIONADO DE BC, DE Y FG CON UNA SECUENCIA DE AMINOACIDOS ALTERADA CON RESPECTO A LA SECUENCIA DEL BUCLE CORRESPONDIENTE DEL DOMINIO DE 10Fn3 HUMANO, Y iii) UNA SECUENCIA DE AMINOACIDOS CON UNA IDENTIDAD DE AL MENOS EL 60% CON LA SEC ID Nº 1; REFERS TO A polypeptide it deimmunized comprising: a) an N-terminal comprising a first tenth fibronectin type III (10Fn3) having i) BUCLES AB, BC, CD, DE, EF and FG, ii) It is having at least one loop selected from BC, DE and FG with an amino acid sequence ALTERED REGARDING SEQUENCE LOOP FOR DOMAIN OF HUMAN 10Fn3, and iii) an amino acid sequence with an identity of at least 60% WITH SEQ ID NO: 1; B) UN DOMINIO C-TERMINAL QUE CONSTA DE UN SEGUNDO DECIMO DOMINIO DE FIBRONECTINA DE TIPO III (10Fn3) QUE POSEE: i) BUCLES AB, BC, CD, DE, EF Y FG, ii) TIENE AL MENOS UN BUCLE SELECCIONADO DE BC, DE Y FG CON UNA SECUENCIA DE AMINOACIDOS ALTERADA CON RESPECTO A LA SECUENCIA DEL BUCLE CORRESPONDIENTE DEL DOMINIO DE 10Fn3 HUMANO, Y iii) UNA SECUENCIA DE AMINOACIDOS CON UNA IDENTIDAD DE AL MENOS EL 60% CON LA SEC ID Nº 1; B) A C-terminal domain comprising a SECOND tenth fibronectin type III (10Fn3) having: i) LOOPS AB, BC, CD, DE, EF and FG, ii) at least one member selected LOOP BC , DE and FG with an amino acid sequence altered from loop sequence DOMAIN FOR HUMAN 10Fn3, and iii) an amino acid sequence with an identity of at least 60% with SEQ ID NO: 1; DONDE AMBOS DOMINIOS ESTAN LIGADOS POR UN POLIPEPTIDO SELECCIONADO DE UN ENGARCE BASADO EN GLICINA-SERINA, GLICINA-PROLINA O LA SECUENCIA DE AMINOACIDOS DE SEC ID Nº: 20. DICHO POLIPEPTIDO ADEMAS COMPRENDE UNO O MAS RESTOS FARMACOCINETICOS TALES COMO UN RESTO POLIOXIALQUILENO COMO POLIETILENGLICOL, ACIDO SIALICO, ALBUMINA SERICA HUMANA, IgG, ENTRE OTROS. WHERE both domains are linked by a selected polypeptide a linker BASED GLICINA-serine, glycine-proline or the amino acid sequence SEQ ID NO: 20. Said polypeptide further comprises one or more residues Pharmacokinetics such as polyoxyalkylene moiety as polyethylene glycol, sialic acid, HUMAN SERUM aLBUMIN, IgG, among others. SE REFIERE TAMBIEN A UN PROCEDIMENTO DE OBTENCION YA UNA COMPOSICION FARMACEUTICA. ALSO it REFERS TO A PROCESS FOR OBTAINING AND A PHARMACEUTICAL COMPOSITION. DICHOS POLIPEPTIDOS SON UTILES EN EL DIAGNOSTICO, INVESTIGACION Y TERAPIA SUCH polypeptides are useful in diagnosis, Research and Therapy
PE2009000713A 2008-05-22 2009-05-21 Frame domain proteins based multivalent fibronectin PE19312009A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US12865108P true 2008-05-22 2008-05-22
US21298209P true 2009-04-17 2009-04-17
US17839509P true 2009-05-14 2009-05-14

Publications (1)

Publication Number Publication Date
PE19312009A1 true PE19312009A1 (en) 2009-12-31

Family

ID=41340736

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000713A PE19312009A1 (en) 2008-05-22 2009-05-21 Frame domain proteins based multivalent fibronectin

Country Status (8)

Country Link
US (4) US8221765B2 (en)
EP (2) EP2799448A1 (en)
JP (1) JP2011520961A (en)
CN (1) CN102099373A (en)
AR (1) AR071874A1 (en)
PE (1) PE19312009A1 (en)
TW (1) TW201000118A (en)
WO (1) WO2009142773A2 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2552435A1 (en) 2003-12-05 2005-06-23 Compound Therapeutics, Inc. Inhibitors of type 2 vascular endothelial growth factor receptors
WO2008066752A2 (en) 2006-11-22 2008-06-05 Adnexus, A Bristol-Myers Squibb R & D Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
US20100144599A1 (en) * 2007-02-02 2010-06-10 Bristol-Myers Squibb Company Vegf pathway blockade
JP5781762B2 (en) 2007-08-10 2015-09-24 プロテリックス、インク Library of Universal iii type fibronectin binding domain
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
US8680019B2 (en) 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
WO2009058379A2 (en) 2007-10-31 2009-05-07 Medimmune, Llc Protein scaffolds
EP2234646A2 (en) * 2007-12-27 2010-10-06 Novartis AG Improved fibronectin-based binding molecules and their use
CN102007145A (en) 2008-02-14 2011-04-06 百时美施贵宝公司 Targeted therapeutics based on engineered proteins that bind egfr
EP2439212B1 (en) * 2008-05-02 2016-12-21 Novartis AG Improved fibronectin-based binding molecules and uses thereof
AR071874A1 (en) 2008-05-22 2010-07-21 Squibb Bristol Myers Co Frame domain proteins based multivalent fibronectin
WO2010048588A2 (en) * 2008-10-23 2010-04-29 Massachusetts Institute Of Technology Directed engagement of activating fc receptors
TWI496582B (en) 2008-11-24 2015-08-21 Squibb Bristol Myers Co Bispecific egfr/igfir binding molecules
US8067201B2 (en) 2009-04-17 2011-11-29 Bristol-Myers Squibb Company Methods for protein refolding
US20120270797A1 (en) * 2009-08-13 2012-10-25 Massachusetts Institute Of Technology Engineered proteins including mutant fibronectin domains
US9139825B2 (en) 2009-10-30 2015-09-22 Novartis Ag Universal fibronectin type III bottom-side binding domain libraries
WO2011092233A1 (en) * 2010-01-29 2011-08-04 Novartis Ag Yeast mating to produce high-affinity combinations of fibronectin-based binders
KR101747991B1 (en) 2010-04-13 2017-06-19 메디뮨 엘엘씨 Trail r2-specific multimeric scaffolds
EA022983B1 (en) * 2010-04-13 2016-04-29 Бристол-Майерс Сквибб Компани Fibronectin based scaffold domain proteins that bind pcsk9
TW201138808A (en) 2010-05-03 2011-11-16 Squibb Bristol Myers Co Serum albumin binding molecules
ES2573108T3 (en) * 2010-05-26 2016-06-06 Bristol-Myers Squibb Company Based scaffold proteins fibronectin having improved stability
US20140080766A1 (en) * 2011-01-07 2014-03-20 Massachusetts Institute Of Technology Compositions and methods for macromolecular drug delivery
WO2012142515A2 (en) 2011-04-13 2012-10-18 Bristol-Myers Squibb Company Fc fusion proteins comprising novel linkers or arrangements
EP3318880A1 (en) 2011-05-17 2018-05-09 Bristol-Myers Squibb Company Improved methods for the selection of binding proteins
WO2012158678A1 (en) 2011-05-17 2012-11-22 Bristol-Myers Squibb Company Methods for maintaining pegylation of polypeptides
US9522951B2 (en) 2011-10-31 2016-12-20 Bristol-Myers Squibb Company Fibronectin binding domains with reduced immunogenicity
US20140056870A1 (en) * 2012-08-27 2014-02-27 Allergan, Inc. Fusion proteins
BR112015005466A2 (en) 2012-09-13 2017-08-08 Squibb Bristol Myers Co domain scaffold proteins fibronectin-based binding to the myostatin
US9695228B2 (en) * 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
US20150368319A1 (en) * 2013-02-06 2015-12-24 Bristol-Myers Squibb Company Fibronectin type iii domain proteins with enhanced solubility
ES2645634T3 (en) 2013-02-12 2017-12-07 Bristol-Myers Squibb Company Methods protein refolding at high pH
JP2017500003A (en) * 2013-10-14 2017-01-05 ヤンセン バイオテツク,インコーポレーテツド The cysteine ​​engineered fibronectin iii type domain binding molecules
EP3447075A2 (en) 2015-05-15 2019-02-27 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
US20170002058A1 (en) * 2015-06-30 2017-01-05 Regents Of The University Of Minnesota Compositions and methods that involve protein scaffolds that specifically bind to hepatocyte growth factor receptor

Family Cites Families (214)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS6023084B2 (en) 1979-07-11 1985-06-05 Ajinomoto Kk
JPS6253158B2 (en) 1979-09-19 1987-11-09 Takeda Chemical Industries Ltd
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
JPH0115514B2 (en) 1979-09-21 1989-03-17 Takeda Chemical Industries Ltd
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
JPH0114918B2 (en) 1981-05-20 1989-03-14 Takeda Chemical Industries Ltd
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5641648A (en) 1986-11-04 1997-06-24 Protein Polymer Technologies, Inc. Methods for preparing synthetic repetitive DNA
US5514581A (en) 1986-11-04 1996-05-07 Protein Polymer Technologies, Inc. Functional recombinantly prepared synthetic protein polymer
US6018030A (en) 1986-11-04 2000-01-25 Protein Polymer Technologies, Inc. Peptides comprising repetitive units of amino acids and DNA sequences encoding the same
US5770697A (en) 1986-11-04 1998-06-23 Protein Polymer Technologies, Inc. Peptides comprising repetitive units of amino acids and DNA sequences encoding the same
US4863457A (en) 1986-11-24 1989-09-05 Lee David A Drug delivery device
IL85035D0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US4997652A (en) 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
AU632065B2 (en) 1988-09-23 1992-12-17 Novartis Vaccines And Diagnostics, Inc. Cell culture medium for enhanced cell growth, culture longevity and product expression
FR2646437B1 (en) 1989-04-28 1991-08-30 Transgene Sa New DNA sequences, their application as a sequence encoding a signal peptide for secretion of mature proteins by recombinant yeast expression cassettes, transformed yeasts and method of preparation of proteins corresponding
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag Bispecific, oligo, mono- and oligovalent antikoerperkonstrukte, their production and use
JP3039802B2 (en) 1989-07-06 2000-05-08 ザ リージェンツ オブザ ユニバーシティ オブ カリフォルニア Receptors for fibroblast growth factor
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
WO1992002536A1 (en) 1990-08-02 1992-02-20 The Regents Of The University Of Colorado Systematic polypeptide evolution by reverse translation
JP3051145B2 (en) 1990-08-28 2000-06-12 住友製薬株式会社 The novel polyethylene glycol derivatives modified peptides
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
JP3116489B2 (en) 1990-11-30 2000-12-11 千寿製薬株式会社 The sustained release intraocular embedded preparations
US5773574A (en) 1990-12-03 1998-06-30 The Scripps Research Institute Polypeptides for promoting cell attachment
US5235041A (en) 1990-12-28 1993-08-10 Protein Polymer Technologies, Inc. Purification of structurally ordered recombinant protein polymers
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
LU91067I2 (en) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab and its variants and derivatives chemical immuno including immotoxines
US5792742A (en) 1991-06-14 1998-08-11 New York University Fibrin-binding peptide fragments of fibronectin
US5281698A (en) 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
WO1993003172A1 (en) 1991-08-01 1993-02-18 University Research Corporation Systematic polypeptide evolution by reverse translation
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
DE69233528D1 (en) 1991-11-25 2005-07-14 Enzon Inc A process for the production of multivalent antigen-binding proteins
DE69334351D1 (en) 1992-02-06 2011-05-12 Novartis Vaccines & Diagnostic Biosynthetic binding protein for tumor markers
DK0563475T3 (en) 1992-03-25 2000-09-18 Immunogen Inc Conjugates of cell binding agents and derivatives of CC-1065
DE69332377T2 (en) 1992-07-13 2003-07-03 Bionebraska Inc A method for modifying recombinant polypeptides
EP1621554B2 (en) 1992-08-21 2012-08-29 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
RU2139731C1 (en) 1992-11-13 1999-10-20 Айдек Фармасьютикалс Корпорейшн (US Methods of treatment, antibodies, hybridoma
WO1994017097A1 (en) 1993-01-19 1994-08-04 Regents Of The University Of Minnesota Synthetic fibronectin fragments as inhibitors of retroviral infections
AT195065T (en) 1993-02-26 2000-08-15 Santen Pharma Co Ltd Biodegradable scleral
AU8124694A (en) 1993-10-29 1995-05-22 Affymax Technologies N.V. In vitro peptide and antibody display libraries
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5516522A (en) 1994-03-14 1996-05-14 Board Of Supervisors Of Louisiana State University Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5559000A (en) 1995-01-18 1996-09-24 The Scripps Research Institute Encoded reaction cassette
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6369116B1 (en) 1995-06-02 2002-04-09 Oculex Pharmaceuticals, Inc. Composition and method for treating glaucoma
DE19646372C1 (en) 1995-11-11 1997-06-19 Evotec Biosystems Gmbh Conjugates of polypeptide and encoding nucleic acid
DK0937140T3 (en) 1996-06-27 2008-01-28 Vlaams Interuniv Inst Biotech Antibody molecules that specifically interact with a target molecule active site or cleft
GB9618960D0 (en) 1996-09-11 1996-10-23 Medical Science Sys Inc Proteases
US5922676A (en) 1996-09-20 1999-07-13 The Burnham Institute Methods of inhibiting cancer by using superfibronectin
DE69730157T2 (en) 1996-10-17 2005-07-28 Mitsubishi Chemical Corp. Molecule which brings together genotype and phenotype and its applications
WO1998031794A1 (en) 1997-01-17 1998-07-23 Toa Gosei Co., Ltd. Vegf-binding polypeptide
DE69835143T2 (en) 1997-01-21 2007-06-06 The General Hospital Corp., Boston Selection of proteins using RNA-protein fusions
US6261804B1 (en) 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
AU7266698A (en) 1997-04-30 1998-11-24 Enzon, Inc. Polyalkylene oxide-modified single chain polypeptides
DE69827507T2 (en) 1997-06-11 2006-03-09 Borean Pharma A/S Trimerisierendes module
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
DE19742706B4 (en) 1997-09-26 2013-07-25 Pieris Proteolab Ag lipocalin muteins
US6159722A (en) 1997-12-03 2000-12-12 Boehringer Mannheim Gmbh Chimeric serine proteases
AT340870T (en) 1998-04-03 2006-10-15 Compound Therapeutics Inc Addressable protein arrays
ES2278463T3 (en) 1998-12-08 2007-08-01 Biovation Limited Method to reduce immunogenicity of proteins.
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
GB9827228D0 (en) 1998-12-10 1999-02-03 Univ Nottingham Cancer detection method and reagents
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
WO2000034784A1 (en) 1998-12-10 2000-06-15 Phylos, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6524583B1 (en) 1999-04-28 2003-02-25 Board Of Regents, The University Of Texas System Antibody methods for selectively inhibiting VEGF
AU781783B2 (en) 1999-07-27 2005-06-16 Bristol-Myers Squibb Company Peptide acceptor ligation methods
DK1242401T3 (en) 1999-11-24 2007-05-07 Immunogen Inc Cytotoxic agents comprising taxanes and their therapeutic use
WO2001072829A2 (en) 2000-03-31 2001-10-04 Institut Pasteur Peptides blocking vascular endothelial growth factor (vegf)-mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof
AU6848101A (en) 2000-06-15 2001-12-24 Univ Texas Regulatable, catalytically active nucleic acids
ES2564161T3 (en) 2000-07-11 2016-03-18 Research Corporation Technologies, Inc Polypeptides artificial antibodies
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US7417130B2 (en) 2000-09-08 2008-08-26 University Of Zurich Collection of repeat proteins comprising repeat modules
AU9696201A (en) 2000-09-29 2002-04-08 Schering Corp Pegylated interleukin-10
JP2004526419A (en) 2000-10-16 2004-09-02 フィロス インク. Protein scaffolds for antibody mimics and other binding proteins
US7598352B2 (en) * 2000-11-17 2009-10-06 University Of Rochester Method of identifying polypeptide monobodies which bind to target proteins and use thereof
JP2004514702A (en) 2000-11-29 2004-05-20 オキュレックス ファーマシューティカルズ, インコーポレイテッド Intraocular implant for preventing transplant rejection in the eye
EP1341912B1 (en) 2000-12-13 2009-05-20 Anaphore, Inc. Method for the identification and isolation of binding polypeptides from combinatorial libraries of proteins having the scaffold structure of c-type lectin-like domains
US6509027B2 (en) 2001-02-12 2003-01-21 Supergen, Inc. Injectable pharmaceutical composition comprising coated particles of camptothecin
WO2002081497A2 (en) 2001-04-04 2002-10-17 University Of Rochester αξβ3 INTEGRIN-BINDING POLYPEPTIDE MONOBODIES AND THEIR USE
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
US20040175756A1 (en) 2001-04-26 2004-09-09 Avidia Research Institute Methods for using combinatorial libraries of monomer domains
AU2002256371B2 (en) 2001-04-26 2008-01-10 Amgen Mountain View Inc. Combinatorial libraries of monomer domains
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
US20050048512A1 (en) 2001-04-26 2005-03-03 Avidia Research Institute Combinatorial libraries of monomer domains
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US20030004561A1 (en) 2001-06-28 2003-01-02 Steve Bigus Peeling sheath for self-expanding stent
AU2002342672A1 (en) 2001-09-11 2003-03-24 Nascacell Gmbh Method for screening for inhibitors of protein/protein interaction and corresponding ribozymes
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
AU2001298053A1 (en) 2001-09-27 2003-04-14 Pieris Proteolab Ag Muteins of apolipoprotein D
WO2003049684A2 (en) 2001-12-07 2003-06-19 Centocor, Inc. Pseudo-antibody constructs
US20080193445A1 (en) 2002-01-18 2008-08-14 Liliane Goetsch Novel anti-IGF-IR antibodies and uses thereof
US7241444B2 (en) 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
CA2662899A1 (en) 2002-02-22 2003-09-04 Schering Corporation Pharmaceutical formulations of antineoplastic agents, in particular temozolomide, processes of making and using the same
ES2347543T3 (en) 2002-03-04 2010-11-02 Imclone Llc human antibodies specific for KDR and their uses.
US7332585B2 (en) 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
WO2003104418A2 (en) 2002-06-06 2003-12-18 Research Corporation Technologies, Inc. Reconstituted polypeptides
US8034904B2 (en) 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
AU2003239777A1 (en) 2002-07-05 2004-01-23 Borean Pharma A/S Multimerised growth hormone fusion proteins
EP1539941A4 (en) 2002-08-27 2006-11-29 Adzymes and uses thereof
US20050074865A1 (en) 2002-08-27 2005-04-07 Compound Therapeutics, Inc. Adzymes and uses thereof
US20040259155A1 (en) 2002-09-30 2004-12-23 Compound Therapeutics, Inc. Methods of engineering spatially conserved motifs in polypeptides
EP1558640B1 (en) 2002-10-29 2011-04-13 Anaphore, Inc. Trimeric binding proteins for trimeric cytokines
US20070178082A1 (en) 2002-11-08 2007-08-02 Ablynx N.V. Stabilized single domain antibodies
JP2007528201A (en) 2003-03-14 2007-10-11 ファルマシア・コーポレーション Antibodies against IGF-i receptor for the treatment of cancer
NZ561162A (en) 2003-04-23 2009-11-27 Hoffmann La Roche Human granzyme B protease variant wherein cystein 228 is mutated to phenylalanine
WO2005047714A1 (en) 2003-11-17 2005-05-26 Telezygology Inc Fasteners and other assemblies
US7579157B2 (en) 2003-07-10 2009-08-25 Hoffmann-La Roche Inc. Antibody selection method against IGF-IR
US7053701B2 (en) 2003-11-04 2006-05-30 Vice Michael W Power amplifier output stage with multiple power states and improved efficiency
US20060228355A1 (en) 2003-11-07 2006-10-12 Toon Laeremans Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor
CA2552435A1 (en) 2003-12-05 2005-06-23 Compound Therapeutics, Inc. Inhibitors of type 2 vascular endothelial growth factor receptors
US20080220049A1 (en) * 2003-12-05 2008-09-11 Adnexus, A Bristol-Myers Squibb R&D Company Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins
MXPA06009072A (en) 2004-02-09 2007-03-29 Human Genome Sciences Inc Albumin fusion proteins.
CN1980952A (en) 2004-02-23 2007-06-13 伯瑞恩药物私人有限公司 Multimerised HIV fusion inhibitors
WO2005080418A2 (en) 2004-02-23 2005-09-01 Borean Pharma A/S Multimerised hiv fusion inhibitors
US20060182783A1 (en) 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
US20070059336A1 (en) 2004-04-30 2007-03-15 Allergan, Inc. Anti-angiogenic sustained release intraocular implants and related methods
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
WO2005110374A1 (en) 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
JP2008512352A (en) 2004-07-17 2008-04-24 イムクローン システムズ インコーポレイティド The novel tetravalent bispecific antibody
US7597884B2 (en) * 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
BRPI0516308A2 (en) 2004-10-04 2010-06-15 Qlt Usa Inc fluid composition, methods of treating a disease or disorder, the methods local or systemic release of a biological agent, implants, method of forming an implant kit biological agent and uses a fluid composition
DE102004049479A1 (en) 2004-10-11 2006-04-13 Scil Proteins Gmbh Protein conjugates for use in therapy, diagnosis and chromatography
WO2006053568A1 (en) 2004-11-22 2006-05-26 Borean Pharma Aps Tnf antagonists
EP1814988A2 (en) 2004-11-26 2007-08-08 Pieris AG Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4)
CA2589484A1 (en) 2004-12-02 2006-06-08 Schering Corporation Methods of using temozolomide formulation intrathecally in the treatment of cancers
CN101163501A (en) 2005-02-23 2008-04-16 梅里麦克制药股份有限公司 Bispecific binding agents for modulating biological activity
US20070269422A1 (en) 2006-05-17 2007-11-22 Ablynx N.V. Serum albumin binding proteins with long half-lives
FR2888850B1 (en) 2005-07-22 2013-01-11 Pf Medicament New anti-FMI-IR antibodies and their applications
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20070072933A1 (en) 2005-09-26 2007-03-29 Peyman Gholam A Delivery of an ocular agent
US8097438B2 (en) * 2005-10-07 2012-01-17 The Regents Of The University Of California Nucleic acids encoding modified cytochrome P450 enzymes and methods of use thereof
BRPI0613401A2 (en) 2005-10-18 2011-01-11 Allergan Inc eye therapy using derivatives of glucocorticoids that selectively penetrate tissues in the posterior segment
WO2007053807A2 (en) 2005-10-31 2007-05-10 Wisconsin Alumni Research Foundation Calcitriol for treating intraocular diseases associated with angiogenesis
US7700292B2 (en) 2005-11-16 2010-04-20 The Bringham And Woman's Hospital, Inc. Allelic form of the HMGA2 gene predisposing women to the formation of leiomyomas
JP5261187B2 (en) * 2005-11-23 2013-08-14 アクセルロン ファーマ, インコーポレイテッド Used to promote the activin -ActRIIa antagonists and bone growth
AU2007293169A1 (en) 2006-02-02 2008-03-13 Allergan, Inc. Compositions and methods for the treatment of ophthalmic disease
JP5161796B2 (en) * 2006-02-24 2013-03-13 シエシー ファルマセウティチィ ソシエタ ペル アチオニ Anti-amyloid immunogenic compositions, methods, and uses
KR20090005010A (en) * 2006-04-21 2009-01-12 트랜스진 에스.에이. Hpv-18-based papillomavirus vaccine
ES2661952T3 (en) 2006-08-04 2018-04-04 Medimmune Limited human antibodies against ERBB2
WO2008031098A1 (en) * 2006-09-09 2008-03-13 The University Of Chicago Binary amino acid libraries for fibronectin type iii polypeptide monobodies
WO2008048970A2 (en) * 2006-10-16 2008-04-24 The Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Synthetic antibodies
WO2008066752A2 (en) 2006-11-22 2008-06-05 Adnexus, A Bristol-Myers Squibb R & D Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
US20100144599A1 (en) 2007-02-02 2010-06-10 Bristol-Myers Squibb Company Vegf pathway blockade
EP2129397B1 (en) 2007-03-02 2018-10-31 Amgen, Inc. Methods and compositions for treating tumor diseases
US20080268051A1 (en) 2007-04-30 2008-10-30 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
EP2738257A1 (en) 2007-05-22 2014-06-04 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
US8680019B2 (en) 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
JP5781762B2 (en) 2007-08-10 2015-09-24 プロテリックス、インク Library of Universal iii type fibronectin binding domain
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
WO2009025806A2 (en) 2007-08-20 2009-02-26 Adnexus, A Bristol-Myers Squibb R & D Company Use of vegfr-2 inhibitors for treating metastatic cancer
CN102099055A (en) 2007-10-04 2011-06-15 津莫吉尼蒂克斯公司 B7 family member zb7h6 and related compositions and methods
WO2009058379A2 (en) 2007-10-31 2009-05-07 Medimmune, Llc Protein scaffolds
US20110034384A1 (en) 2007-11-28 2011-02-10 Bristol-Myers Squibb Company COMBINATION VEGFR2 THERAPY WITH mTOR INHIBITORS
JP2011507529A (en) 2007-12-19 2011-03-10 セントコア・オーソ・バイオテツク・インコーポレーテツド Alternate of the scaffold protein fusion phage display through the fusion to the M13 phage pIX
EP2234646A2 (en) 2007-12-27 2010-10-06 Novartis AG Improved fibronectin-based binding molecules and their use
CN102007145A (en) 2008-02-14 2011-04-06 百时美施贵宝公司 Targeted therapeutics based on engineered proteins that bind egfr
EP2439212B1 (en) * 2008-05-02 2016-12-21 Novartis AG Improved fibronectin-based binding molecules and uses thereof
AR071874A1 (en) 2008-05-22 2010-07-21 Squibb Bristol Myers Co Frame domain proteins based multivalent fibronectin
US8415291B2 (en) 2008-10-31 2013-04-09 Centocor Ortho Biotech Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
PT2356269T (en) 2008-10-31 2016-09-13 Janssen Biotech Inc Fibronectin type iii domain based scaffold compositions, methods and uses
TWI496582B (en) * 2008-11-24 2015-08-21 Squibb Bristol Myers Co Bispecific egfr/igfir binding molecules
KR20110104052A (en) 2008-12-16 2011-09-21 노파르티스 아게 Yeast display systems
EP2396000A1 (en) 2009-02-11 2011-12-21 Bristol-Myers Squibb Company Combination vegfr2 therapy with temozolomide
RU2562700C2 (en) 2009-02-12 2015-09-10 Янссен Байотек, Инк. Compositions, methods of producing and using fibronectin type iii domain based scaffold
US8067201B2 (en) 2009-04-17 2011-11-29 Bristol-Myers Squibb Company Methods for protein refolding
US20120270797A1 (en) 2009-08-13 2012-10-25 Massachusetts Institute Of Technology Engineered proteins including mutant fibronectin domains
US9139825B2 (en) 2009-10-30 2015-09-22 Novartis Ag Universal fibronectin type III bottom-side binding domain libraries
WO2011051466A1 (en) 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
US20110123545A1 (en) 2009-11-24 2011-05-26 Bristol-Myers Squibb Company Combination of vegfr2 and igf1r inhibitors for the treatment of proliferative diseases
WO2011092233A1 (en) 2010-01-29 2011-08-04 Novartis Ag Yeast mating to produce high-affinity combinations of fibronectin-based binders
US8961977B2 (en) 2010-02-12 2015-02-24 University Of Rochester Antigenic mimics of discontinuous epitopes of pathogen recognized by broadly neutralizing antibodies
US8927693B2 (en) 2010-02-18 2015-01-06 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind IL-23
KR101747991B1 (en) 2010-04-13 2017-06-19 메디뮨 엘엘씨 Trail r2-specific multimeric scaffolds
EA022983B1 (en) 2010-04-13 2016-04-29 Бристол-Майерс Сквибб Компани Fibronectin based scaffold domain proteins that bind pcsk9
US8569227B2 (en) 2010-04-30 2013-10-29 Janssen Biotech, Inc. Stabilized fibronectin domain compositions, methods and uses
TW201138808A (en) 2010-05-03 2011-11-16 Squibb Bristol Myers Co Serum albumin binding molecules
ES2573108T3 (en) 2010-05-26 2016-06-06 Bristol-Myers Squibb Company Based scaffold proteins fibronectin having improved stability
CN107903321A (en) 2010-07-30 2018-04-13 诺华有限公司 Fibronectin cradle molecules and libraries thereof
CN103380143B (en) 2010-12-22 2016-01-06 百时美施贵宝公司 Il-23 binding domain protein scaffold based on fibronectin
WO2012142515A2 (en) 2011-04-13 2012-10-18 Bristol-Myers Squibb Company Fc fusion proteins comprising novel linkers or arrangements
EP3318880A1 (en) 2011-05-17 2018-05-09 Bristol-Myers Squibb Company Improved methods for the selection of binding proteins
WO2012158678A1 (en) 2011-05-17 2012-11-22 Bristol-Myers Squibb Company Methods for maintaining pegylation of polypeptides
MX358827B (en) 2011-09-27 2018-09-05 Janssen Biotech Inc Fibronectin type iii repeat based protein scaffolds with alternative binding surfaces.

Also Published As

Publication number Publication date
WO2009142773A4 (en) 2010-09-23
CN102099373A (en) 2011-06-15
WO2009142773A9 (en) 2010-11-11
AR071874A1 (en) 2010-07-21
US9902762B2 (en) 2018-02-27
EP2291399A2 (en) 2011-03-09
WO2009142773A8 (en) 2010-06-17
US20090299040A1 (en) 2009-12-03
TW201000118A (en) 2010-01-01
US8221765B2 (en) 2012-07-17
US20140349929A1 (en) 2014-11-27
EP2291399B1 (en) 2014-06-25
JP2011520961A (en) 2011-07-21
US20130012435A1 (en) 2013-01-10
EP2799448A1 (en) 2014-11-05
WO2009142773A2 (en) 2009-11-26
US20180265572A1 (en) 2018-09-20
WO2009142773A3 (en) 2010-08-05
US8728483B2 (en) 2014-05-20

Similar Documents

Publication Publication Date Title
Vandenberg et al. Characterization of a type IV collagen major cell binding site with affinity to the alpha 1 beta 1 and the alpha 2 beta 1 integrins.
Aumailley et al. Structure and biological activity of the extracellular matrix
Gilon et al. Backbone cyclization: a new method for conferring conformational constraint on peptides
KR100650929B1 (en) Apolipoprotein A-I Agonists and their use to treat dyslipidemic disorders
Amagai Adhesion molecules. I: Keratinocyte-keratinocyte interactions; cadherins and pemphigus
AU765753B2 (en) Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
EP1516184B1 (en) Cell-selective delivery system
Takeuchi et al. Direct and rapid cytosolic delivery using cell-penetrating peptides mediated by pyrenebutyrate
Tyndall et al. Over one hundred peptide-activated G protein-coupled receptors recognize ligands with turn structure
Marcinkiewicz et al. EC3, a novel heterodimeric disintegrin from Echis carinatus venom, inhibits α4 and α5 integrins in an RGD-independent manner
Pfaff et al. Integrin and Arg-Gly-Asp dependence of cell adhesion to the native and unfolded triple helix of collagen type VI
KR100608558B1 (en) Cytoplasmic Transduction Peptides and Uses thereof
KERN et al. Interaction of type IV collagen with the isolated integrins α1β1 and α2β1
McDowell et al. Mambin, a potent glycoprotein IIb-IIIa antagonist and platelet aggregation inhibitor structurally related to the short neurotoxins
Curnis et al. Spontaneous formation of L-isoaspartate and gain of function in fibronectin
Liscum et al. Domain structure of 3-hydroxy-3-methylglutaryl coenzyme A reductase, a glycoprotein of the endoplasmic reticulum.
US5491130A (en) Peptide inhibitors of fibronectin and related collagen-binding proteins
Gottschalk et al. The structures of integrins and integrin–ligand complexes: implications for drug design and signal transduction
KR100810927B1 (en) Membrane penetrating peptides and uses thereof
KR101651703B1 (en) FGF21 Mutants and Uses Thereof
Muir et al. Design and Chemical Synthesis of a Neoprotein Structural Model for the Cytoplasmic Domain of a Multisubunit Cell-Surface Receptor: Integrin. alpha. IIb. beta. 3 (Platelet GPIIb-IIIa)
Tschopp et al. Clusterin, the human apolipoprotein and complement inhibitor, binds to complement C7, C8 beta, and the b domain of C9.
Malinda et al. The laminins
Farrera-Sinfreu et al. Cell-penetrating cis-γ-amino-L-proline-derived peptides
Rottier et al. Predicted membrane topology of the coronavirus protein E1

Legal Events

Date Code Title Description
FD Application declared void or lapsed